Protalix BioTherapeutics
PLX
PLX
66 hedge funds and large institutions have $17.9M invested in Protalix BioTherapeutics in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
94% more funds holding
Funds holding: 34 → 66 (+32)
8.17% more ownership
Funds ownership: 5.12% → 13.29% (+8.2%)
Holders
66
Holding in Top 10
–
Calls
$2.82M
Puts
$838K
Top Buyers
| 1 | +$6.02M | |
| 2 | +$1.74M | |
| 3 | +$1.32M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$981K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$865K |
Top Sellers
| 1 | -$1.31M | |
| 2 | -$504K | |
| 3 | -$494K | |
| 4 |
Two Sigma Investments
New York
|
-$331K |
| 5 |
Millennium Management
New York
|
-$156K |